Google Platform Changes Spur Pharma Rethinking Of Search Engine Ads
This article was originally published in The Tan Sheet
Executive Summary
Widespread use of paid ads that display disease-specific website address differing significantly from destination hyperlink for branded product will end in January.
You may also be interested in...
Google Creates New Formats To Include Risk Information In Sponsored Search Results
Click-through rate on health condition search results declined dramatically since FDA citations, company says.
Internet Promotions Must Be Redesigned After FDA Cites Sponsored Web Links
Firms will need to redesign sponsored links that appear on Internet search engines or forgo using them at all, food and drug attorneys suggest following the agency's recent cluster of letters citing the promotions
BrainStorm’s ALS Treatment NurOwn, Filed Over Protest, Will Get US FDA Panel Review
A November 2022 refuse-to-file letter cited clinical and statistical issues for the stem cell therapy, which failed its Phase III clinical efficacy endpoint. However, BrainStorm has consistently asserted that NurOwn demonstrated benefit in patients with less advanced disease at baseline, and it is encouraged by regulatory flexibility FDA recently has shown for the neurodegenerative disease.